Abstract
Elevated alkaline phosphatase (ALP) levels are associated with cerebral small vascular diseases, such as silent brain infarction and cerebral white matter hyperintensity (cWMH), but few prospective data are available for cerebral microbleeds (CMBs). The aim of the study was to investigate associations between serum ALP levels and CMBs in acute ischemic stroke patients with atrial fibrillation and/or rheumatic heart disease. This prospective study involved consecutively recruited acute ischemic stroke patients with atrial fibrillation and/or rheumatic heart disease treated at two large tertiary care hospitals in southwestern China. We used logistic regression to examine the relationships between ALP levels and CMBs. Of 128 patients (56 males; mean age, 68 years) included, 71 (55.5%) patients had CMBs. Compared with the first tertile of ALP concentration, participants in the third tertile were 3.59 times more likely to have multi-CMBs (2) [95% confidence interval (CI): 1.21-10.71; P = 0.02] after adjusting for age, gender, smoking habits, drinking habits, ALT (alanine transaminase) levels, AST (aspartate transaminase) levels, renal impairment and cWMH.
Keywords: Acute ischemic stroke, alkaline phosphatase, cerebral microbleeds, atrial fibrillation, rheumatic heart disease.
Current Neurovascular Research
Title:High Serum Alkaline Phosphatase Levels in Relation to Multi-Cerebral Microbleeds in Acute Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease
Volume: 13 Issue: 4
Author(s): Junfeng Liu, Deren Wang, Jie Li, Yao Xiong, Bian Liu, Chenchen Wei, Simiao Wu and Ming Liu
Affiliation:
Keywords: Acute ischemic stroke, alkaline phosphatase, cerebral microbleeds, atrial fibrillation, rheumatic heart disease.
Abstract: Elevated alkaline phosphatase (ALP) levels are associated with cerebral small vascular diseases, such as silent brain infarction and cerebral white matter hyperintensity (cWMH), but few prospective data are available for cerebral microbleeds (CMBs). The aim of the study was to investigate associations between serum ALP levels and CMBs in acute ischemic stroke patients with atrial fibrillation and/or rheumatic heart disease. This prospective study involved consecutively recruited acute ischemic stroke patients with atrial fibrillation and/or rheumatic heart disease treated at two large tertiary care hospitals in southwestern China. We used logistic regression to examine the relationships between ALP levels and CMBs. Of 128 patients (56 males; mean age, 68 years) included, 71 (55.5%) patients had CMBs. Compared with the first tertile of ALP concentration, participants in the third tertile were 3.59 times more likely to have multi-CMBs (2) [95% confidence interval (CI): 1.21-10.71; P = 0.02] after adjusting for age, gender, smoking habits, drinking habits, ALT (alanine transaminase) levels, AST (aspartate transaminase) levels, renal impairment and cWMH.
Export Options
About this article
Cite this article as:
Liu Junfeng, Wang Deren, Li Jie, Xiong Yao, Liu Bian, Wei Chenchen, Wu Simiao and Liu Ming, High Serum Alkaline Phosphatase Levels in Relation to Multi-Cerebral Microbleeds in Acute Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease, Current Neurovascular Research 2016; 13 (4) . https://dx.doi.org/10.2174/1567202613666160817095623
DOI https://dx.doi.org/10.2174/1567202613666160817095623 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Current Pharmaceutical Design Biochemical Strategies to Anticoagulation: A Comparative Overview
Current Vascular Pharmacology Systemic Sclerosis-Related Pulmonary Hypertension: Unique Characteristics and Future Treatment Targets
Current Pharmaceutical Design Pulmonary Arterial Hypertension
Current Vascular Pharmacology Nano-Systems for Advanced Therapeutics and Diagnosis of Atherosclerosis
Current Pharmaceutical Design Vitamin E-Related Inhibition of Monocyte 5-Lipoxygenase and Cardiovascular Outcome in Maintenance Hemodialysis Patients
Recent Patents on Inflammation & Allergy Drug Discovery Thioridazine: The Good and the Bad
Recent Patents on Anti-Infective Drug Discovery Cardiac Biomarkers in Stroke, Alzheimer’s Disease, and Other Dementia. Are They of Use? A Brief Overview of Data from Recent Investigations
CNS & Neurological Disorders - Drug Targets Vitamin D: A Pleiotropic Hormone with Possible Psychotropic Activities
Current Medicinal Chemistry Role of the Autonomic Nervous System and Neuropeptides in the Development of Obesity in Humans: Targets for Therapy?
Current Pharmaceutical Design The Role of Dietary Fats in Hypertension, Obesity and Insulin Resistance: A Comparative Study of Animals and Humans in Fetal and Adult Life
Current Nutrition & Food Science Nattokinase: An Updated Critical Review on Challenges and Perspectives
Cardiovascular & Hematological Agents in Medicinal Chemistry Vitamin D, Sunlight and Cancer Connection
Anti-Cancer Agents in Medicinal Chemistry Hedgehog Signaling and Urological Cancers
Current Drug Targets Therapeutic Agents Against COVID-19 with Clinical Evidence
Current Pharmaceutical Design Genetic and Environmental Determinants of Early Vascular Ageing (EVA)
Current Vascular Pharmacology 24-Hour Blood Pressure Control – A Predictor for Clinical Outcomes
Current Hypertension Reviews Prostaglandin EP Receptor Subtypes Involved in Regulating HCO3- Secretion from Gastroduodenal Mucosa
Current Pharmaceutical Design Does Caffeine Affect Cardiovascular Responses?
Vascular Disease Prevention (Discontinued) Potential Targets for Intervention in Radiation-Induced Heart Disease
Current Drug Targets